Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0020538 (hypertension)
 170,190 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Prazosin hydrochloride, a new antihypertensive agent, is said to be of mild-to-moderate potency when used as a sole agent in mild-to-moderate hypertension and when used in conjunction with other agents in severe hypertension. In our study of 14 patients comparing hydrochlorothiazide with prazosin, the antigypertensive effect of prazosin was less than that of hydrochlorothiazide. The greatest application of prazosin may be in conjunction with thiazide diuretics and beta-adrenergic blocking agents as the second or third drug.
 ...
PMID:Prazosin-new hypertensive agent. A double-blind crossover study in the treatment of hypertension. 1 30

Prazosin (Minipress; Pfizer), a new antihypertensive agent, was investigated in 24 outpatients with uncontrolled hypertension. In 12 patients a single-blind placebo-controlled trial was conducted and in 12 patients an open trial with treatment for a minimum of 16 weeks. Three patients developed postural hypotension and were withdrawn from the trial. Fifteen patients responded to treatment with prazosin and normotensive levels were reached in 9. Ten patients had renal impairment at the start of the study; renal function remained static in 9 and serum urea and creatinine values increased in 1. Prazosin maintains renal function well in severely hypertensive patients and has a relatively low incidence of side-effects, related mainly to postural hypotension which develops unpredictably in some patients. In addition to its extensively documented beneficial effect in mild and moderate forms of hypertension, prazosin is of use in the therapy of patients with severe and uncontrolled hypertension.
 ...
PMID:Prazosin in the therapy of uncontrolled hypertension. 33 73

Prazosin hydrochloride is an orally administered vasodilator that recently became available for the treatment of hypertension. It causes less tachycardia than hydralazine but may produce orthostatic hypotension, particularly after the initial dose. The role of prazosin in therapy is limited because of the risk of a first-dose syncopal reaction, and it appears to be indicated primarily in patients who cannot tolerate hydralazine hydrochloride or sympathetic depressant drugs. Like other antihypertensive agents, prazosin should be given with a diuretic.
 ...
PMID:Evaluation of a new antihypertensive agent: prazosin hydrochloride (Minipress). 57 90

The observations of a 16-week Tensiomin therapy of 10 hypertensive patients treated with hemodialysis have been discussed. The patients have been treated for about 5 years with hemodialysis, suffered from anuria and required besides systhematical ultrafiltration a combination antihypertensive therapy. Tensiomin was combined with Minipress, Trasicor, Depressan, Estulic and Corinfar by using three- or four-drug combinations. In the course of the administration of Tensiomin the doses of the other antihypertensive drugs could be decreased by 50% on average, while the blood pressure of the patients was normalized. By controlling the patients on weeks 1, 4, 12 and 16 of therapy toxic side-effects or notable pathological changes of the examined laboratory parameters (WBC, serum total protein, Na, K, Ca, P, bilirubin, blood sugar and SGOT values) were not seen. It has been concluded that Tensiomin is an effective drug in combination therapy applied for normalizing the hypertension of dialysed patients.
 ...
PMID:Use of tensiomin (captopril) in the antihypertensive treatment of haemodialysis patients. 219 78

Prazosin (Minipress) monotherapy was given to 152 patients with essential hypertension for one year in a multi-center study involving 13 hospitals and university clinics. In three centers serum levels of total cholesterol, HDL-cholesterol and triglycerides were also determined in 32 patients with hypertension and hyper/dys-lipoproteinemia. As a consequence of Minipress monotherapy significant decreases were found in serum level of cholesterol (after three months and also after one year), triglycerides (after one year), while the serum concentration of HDL-cholesterol increased. Atherogenic index (a ratio of total cholesterol over HDL-cholesterol) was significantly decreased by Minipress. As new data showing a causative correlation between hypertension and hyperlipoproteinemia were published in the literature authors, on the basis of their results, suggest to determine lipid profile in every patient with hypertension. They regard Minipress as the first line drug in young patients with "familial dyslipidemic hypertension". When choosing an antihypertensive drug metabolic side effects should be taken into consideration.
 ...
PMID:[The anti-lipidemic effect of Minipress]. 236 61

The specific competitive alpha 1-postsynaptic blocking action and haemodynamic effects of prazosin (Minipress) have been summarized. Prazosin causes dilatation of arterioles and veins, reduces total peripheral resistance as well as preload and afterload. Cardiac output does not change at rest, stroke volume and subsequent cardiac output increase during exercise. The changes in heart rate have non-significant. It does not cause sympathetic counter-regulation, plasma renin activity does not increase, aldosterone level decreases, salt- and fluid retention may rarely be observed. It does not provoke angina. The authors report on the results of their examinations with the first dose of prazosin in 61 patients (in 33 cases by the double-blind cross-over method by placebo control), and summarize the observations made with the drug in long-term treatment in Hungary. The authors and other teams used prazosin as a long-term treatment (of approximately 3 months) in combination with other drugs in a total of 344 patients, and as monotherapy in 159 patients. In the course of combination treatment side-effects were observed in 15% of the patients (dizziness, headache, weakness, occasionally palpitation). During monotherapy, side-effects occurred in 12% of the patients (tachycardia, headache, weakness, dizziness). Hungarian results confirm the usefulness of prazosin in all stages of hypertension. It is effective in 30-35% of the cases as a monotherapy (this rate is congruent with the efficacy of beta-blockers, calcium antagonists and antihypertensive drugs of central action). Earlier prazosin had been used as a third agent in combination treatment of hypertension.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:The mechanism of the action of Minipress. Examinations in hypertension. 257 64

The efficacy and safety of prazosin GITS (gastro-intestinal therapeutic system), a new extended-release once-a-day formulation, were assessed both as monotherapy in mild essential hypertension and in combination with a diuretic in moderate essential hypertension in two multicenter, double-blind, placebo-controlled trials. Prazosin GITS (Minipress XL) given once daily in doses of either 10 or 20 mg significantly reduced sitting and standing systolic and diastolic blood pressure compared with placebo in both mild and moderate essential hypertension. There were minimal, clinically insignificant changes in heart rate following prazosin-GITS treatment (2.5, 10, and 20 mg) compared with placebo treatment. Prazosin GITS was well tolerated; the most common adverse experiences reported were headache, dizziness, and fatigue. All adverse experiences in the moderate hypertension group and the majority (91 percent) in the mild hypertension group were mild-to-moderate in severity. The results from these multicenter trials demonstrate the efficacy and safety of this new extended-release once-a-day formulation of prazosin in the treatment of patients with mild and moderate essential hypertension.
 ...
PMID:Efficacy and safety of Minipress XL, a new once-a-day formulation of prazosin. 266 73

Multicenter study of the effectiveness and safety of prazosin (Minipress) in patients with arterial hypertension was carried out in 15 medical centers. Of 366 patients who entered the study, 328 persons satisfying all the protocol conditions were included into the final analysis. The treatment lasted 3 months. Highly significant decrease of systolic and diastolic blood pressure was obtained in all periods of observation. In about two-thirds of patients Minipress was effective as a single drug and in the remaining persons the decrease of blood pressure was achieved using prazosin in combination with other antihypertensive drugs. Patients requiring combination therapy were almost 2 years older (however, the difference was not significant), had higher initial blood pressure and greater body mass. Mean daily doses of Minipress in the monotherapy and combination treatment were 5.6 and 10 mg, respectively. Side effects were observed in 27% of patients, but only in 5% they were the cause of drug withdrawal.
 ...
PMID:[Minipress in the treatment of arterial hypertension in light of results from a multicenter study. I. 3-month treatment: monotherapy versus combination treatment]. 270 Oct 9

Of 218 patients with arterial hypertension, who responded to monotherapy with prazosin (Minipress) during the first 3 months, 178 persons completed the 12-month treatment according to the study protocol. In 9 patients (4.1%) treatment was discontinued because of increase of blood pressure and/or side effects. In the remaining cases patients did not apply for the control examination or the obtained records were incomplete. During all periods of treatment the mean values of systolic and diastolic blood pressure were significantly lower than the corresponding initial values. No significant symptoms of drug tolerance were observed. Mean daily dose of Minipress after 12 months was 5.9 in comparison with 5.6 mg after 3-month therapy. Normal systolic and diastolic pressures at the end of treatment were found in 114 (64%) and 153 (86%) patients, respectively. Full normalization of blood pressure (less than or equal to 140/90) was achieved in 105 (59%) patients. It was found that an important factor determining the antihypertensive effectiveness of Minipress is the initial blood pressure. The inverse correlation between the decrease of systolic pressure and age was found, whereas the age did not affect requiring the drug withdrawal occurred in 27 (14.4%) patients; they were usually the efficacy of Minipress in relation to diastolic blood pressure. Side effects not of moderate intensity and transient character.
 ...
PMID:[Minipress in the treatment of arterial hypertension in light of results from a multicenter study. II. Results of long-term monotherapy]. 270 Oct 10

Prazosin (Minipress; Pfizer), the first purely alpha-blocking antihypertensive agent, was used to treat 22 pregnant patients with moderately severe hypertension (diastolic blood pressure persistently above 95 mmHg at gestational ages ranging from 18 to 33 weeks). Prazosin was used because it is a postsynaptic alpha-blocking agent producing no direct tachycardia or renin stimulation and because its action in producing visceral vasodilation might improve uteroplacental perfusion. Oxprenolol (Trasicor; Ciba), a beta-blocking agent with intrinsic sympathomimetic activity, was added to the prazosin regimen in 12 cases. In this group pregnancy was prolonged for an average of 32 days and 10 infants survived the neonatal period. Fetal loss, mainly due to abortion, was high in the patients who had significant proteinuria, and it was not possible to prolong the pregnancy in these cases. There were no significant maternal, fetal or neonatal side-effects attributable to this combined alpha- and beta-blocking therapy, which may have both theoretical and practical advantages over other current therapies.
 ...
PMID:Prazosin and oxprenolol therapy in pregnancy hypertension. 687 69


1 2 Next >>